BMRN Stock Analysis: Biomarin Pharmaceutical | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 11.298m USD | 12M Return: 6.5% | US09061G1013 | Charts, Fundamentals & Technical Analysis

Lysosomal Storage, Growth Disorders, Metabolic Disorders, Neurological Disorders
Total Rating 29
Safety 66
Buy Signal -0.79
Biotechnology
Sub-Industry Rotation: +3.3
Market Cap: 11.3B
Avg Turnover: 134M
Risk 3d forecast
Volatility30.2%
VaR 5th Pctl4.90%
VaR vs Median-1.29%
Reward TTM
Sharpe Ratio0.22
Rel. Str. IBD37.7
Rel. Str. Peer Group45.3 pctl
Character TTM
Beta0.287
Beta Downside0.395
Hurst Exponent0.439
Choppyness56.3%
Drawdowns 3y
Max DD49.83%
CAGR/Max DD-0.26
CAGR/Mean DD-0.41
EPS (Earnings per Share) EPS (Earnings per Share) of BMRN over the last years for every Quarter: "2021-09": 0.18, "2021-12": -0.32, "2022-03": 0.54, "2022-06": 0.58, "2022-09": 0.45, "2022-12": -0.0013, "2023-03": 0.6, "2023-06": 0.54, "2023-09": 0.46, "2023-12": 0.18, "2024-03": 0.71, "2024-06": 0.96, "2024-09": 0.55, "2024-12": 0.92, "2025-03": 1.13, "2025-06": 1.44, "2025-09": 0.12, "2025-12": 0.46, "2026-03": 0.76, "2026-06": 0.9, "2026-09": 0.02,
EPS CAGR: 9.91%
EPS Trend: 31.7%
Last SUE: 1.28
Qual. Beats: 1
Revenue Revenue of BMRN over the last years for every Quarter: 2021-09: 408.742, 2021-12: 449.81, 2022-03: 519.359, 2022-06: 533.798, 2022-09: 505.344, 2022-12: 537.538, 2023-03: 596.415, 2023-06: 595.275, 2023-09: 581.329, 2023-12: 646.207, 2024-03: 648.833, 2024-06: 712.029, 2024-09: 745.74, 2024-12: 747.313, 2025-03: 745.145, 2025-06: 825.41, 2025-09: 776.133, 2025-12: 874.565, 2026-03: 766.208, 2026-06: 989.708, 2026-09: 1024.646,
Rev. CAGR: 15.12%
Rev. Trend: 99.1%
Last SUE: -2.64
Qual. Beats: -1

Warnings

High Debt/EBITDA With Thin Interest Coverage
Below Sma 200d

Tailwinds

Seasonal Tailwind

Seasonality 11.9 years of data, until 10/2026

Jan -2.1% 21
Feb +0.5% 0
Mar -1.6% 14
Apr +0.8% 4
May -0.6% 0
Jun +2.3% 28
Jul +1.7% 4
Aug +0.7% 4
Sep -6.0% 73
Oct -1.7% 4
Nov ★ +7.5% 64
Dec +1.5% 21

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: BMRN Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a U.S.-based biotechnology company headquartered in San Rafael, California, founded in 1996. It develops and commercializes therapies for life-threatening rare diseases, operating across the United States, Europe, Latin America, the Middle East, and Asia Pacific. The company serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers, and maintains a license and collaboration agreement with Ares Trading S.A.

Its commercial portfolio includes Vimizim (MPS IV type A), Voxzogo (achondroplasia), Naglazyme (MPS VI), Palynziq (phenylketonuria), Brineura (Batten disease), Aldurazyme, and Kuvan. The pipeline features BMN 333, a longer-acting CNP for growth disorders, and BMN 351, an oligonucleotide for Duchenne muscular dystrophy.

BioMarin operates within the orphan drug business model, targeting rare genetic conditions with limited patient populations. This approach typically relies on enzyme replacement therapies and biologics, which often qualify for orphan drug designation and extended market exclusivity periods, supporting premium pricing strategies common in the rare disease segment.

Headlines to Watch Out For
  • VOXZOGO sales accelerate in achondroplasia market
  • PALYNZIQ revenue grows in PKU segment
  • Pipeline assets BMN 333 and BMN 351 advance
Piotroski VR-10 (Strict) 2.0
Net Income: -19.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -6.03 > 1.0
NWC/Revenue: 63.36% < 20% (prev 98.78%; Δ -35.42% < -1%)
CFO/TA 0.06 > 3% & CFO 676.6m > Net Income -19.1m
Net Debt (3.47b) to EBITDA (445.3m): 7.79 < 3
Current Ratio: 2.44 > 1.5 & < 3
Outstanding Shares: last quarter (193.6m) vs 12m ago 0.81% < -2%
Gross Margin: 75.42% > 18% (prev 81.32%; Δ -5.90% > 0.5%)
Asset Turnover: 38.11% > 50% (prev 40.63%; Δ -2.53% > 0%)
Interest Coverage Ratio: 1.32 > 6 (EBIT TTM 180.3m / Interest Expense TTM 136.7m)
Altman Z'' 2.73
A: 0.20 (Total Current Assets 3.92b - Total Current Liabilities 1.60b) / Total Assets 11.6b
B: 0.02 (Retained Earnings 181.7m / Total Assets 11.6b)
C: 0.02 (EBIT TTM 180.3m / Avg Total Assets 9.59b)
D: 1.18 (Book Value of Equity 6.26b / Total Liabilities 5.31b)
Altman-Z'' = 2.73 = A
Beneish M -2.35
DSRI: 1.15 (Receivables 1.08b/790.3m, Revenue 3.66b/3.09b)
GMI: 1.08 (GM 81.32% / 75.42%)
AQI: 1.60 (AQ_t 0.57 / AQ_t-1 0.36)
SGI: 1.18 (Revenue 3.66b / 3.09b)
TATA: -0.06 (NI -19.1m - CFO 676.6m) / TA 11.6b)
Beneish M = -2.35 (Cap -4..+1) = BBB
What is the price of BMRN shares?

As of November 17, 2026, the stock is trading at USD 57.99 with a total of 2,020,680 shares traded. Over the past week, the price has changed by +1.42%, over one month by +6.05%, over three months by -12.98% and over the past year by +6.48%.

Current recommended Stop Loss: 55.70 (which is 3.9% or 1.3 ATR below the current price).

Is BMRN a buy, sell or hold?

Biomarin Pharmaceutical has received a consensus analysts rating of 4.32. Therefore, it is recommended to buy BMRN.

  • StrongBuy: 16
  • Buy: 5
  • Hold: 7
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the BMRN price?
Analysts Target Price 90.8 56.5%
Biomarin Pharmaceutical (BMRN) - Fundamental Data Overview as of 13 November 2026
Market Cap USD = 11.3b (11.3b USD * 1.0 USD.USD)
P/E Forward = 8.6655
P/S = 3.0911
P/B = 1.7688
P/EG = 0.336
Revenue TTM = 3.66b USD
EBIT TTM = 180.3m USD
EBITDA TTM = 445.3m USD
Long Term Debt = 3.51b USD (from longTermDebt, last quarter)
Short Term Debt = 675.2m USD (from shortTermDebt, last quarter)
Debt = 4.21b USD (from shortLongTermDebtTotal, last quarter) + Leases 16.5m
Net Debt = 3.47b USD (calculated: Debt 4.21b - CCE 736.0m)
Enterprise Value = 14.8b USD (11.3b + Debt 4.21b - CCE 736.0m)
Interest Coverage Ratio = 1.32 (Ebit TTM 180.3m / Interest Expense TTM 136.7m)
EV/FCF = 26.47x (Enterprise Value 14.8b / FCF TTM 557.9m)
FCF Yield = 3.78% (FCF TTM 557.9m / Enterprise Value 14.8b)
FCF Margin = 15.26% (FCF TTM 557.9m / Revenue TTM 3.66b)
Net Margin = -0.52% (Net Income TTM -19.1m / Revenue TTM 3.66b)
Gross Margin = 75.42% ((Revenue TTM 3.66b - Cost of Revenue TTM 898.3m) / Revenue TTM)
Gross Margin QoQ = 79.95% (prev 79.51%)
Tobins Q-Ratio = 1.28 (Enterprise Value 14.8b / Total Assets 11.6b)
Interest Expense / Debt = 3.25% (Interest Expense 136.7m / Debt 4.21b)
Taxrate = 27.69% (133.6m / 482.5m)
NOPAT = 130.4m (EBIT 180.3m * (1 - 27.69%))
Current Ratio = 2.44 (Total Current Assets 3.92b / Total Current Liabilities 1.60b)
Debt / Equity = 0.67 (Debt 4.21b / totalStockholderEquity, last quarter 6.26b)
Debt / EBITDA = 7.79 (Net Debt 3.47b / EBITDA 445.3m)
Debt / FCF = 6.22 (Net Debt 3.47b / FCF TTM 557.9m)
Total Stockholder Equity = 6.22b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.20% (Net Income -19.1m / Total Assets 11.6b)
RoE = -0.31% (Net Income TTM -19.1m / Total Stockholder Equity 6.22b)
RoCE = 1.85% (EBIT 180.3m / Capital Employed (Equity 6.22b + L.T.Debt 3.51b))
RoIC = 1.25% (NOPAT 130.4m / Invested Capital 10.5b)
WACC = 5.45% (E(11.3b)/V(15.5b) * Re(6.61%) + D(4.21b)/V(15.5b) * Rd(3.25%) * (1-Tc(0.28)))
Discount Rate = 6.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -60.89 | Cagr: -1.55%
[DCF] Terminal Value 73.10% ; FCFF base≈665.1m ; Y1≈583.3m ; Y5≈471.3m
[DCF] Fair Price = 21.14 (EV 7.56b - Net Debt 3.47b = Equity 4.09b / Shares 193.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 31.66 | EPS CAGR: 9.91% | SUE: 1.28 | # QB: 1
Revenue Correlation: 99.07 | Revenue CAGR: 15.12% | SUE: -2.64 | # QB: -1
EPS current Year (2026-12-31): EPS=3.03 | Chg30d=-21.67% | Revisions=-25% | GrowthEPS=-3.9% | GrowthRev=+20.1%
EPS next Year (2027-12-31): EPS=6.32 | Chg30d=-10.41% | Revisions=+0% | GrowthEPS=+108.9% | GrowthRev=+14.9%
[Analyst] Revisions Ratio: -25% (up=0, down=1)